Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Bone

Showing results (141-150 of 192) with videos related to

Pageof 20
Sort By:
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|September 24, 2018
The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studiesD L Kendler, A Chines, M L Brandi, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 4, 2011
Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trialsE Barrett-Connor, A S Swern, C M Hustad, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|October 20, 2019
Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumabD L Kendler, H G Bone, F Massari, et al.
The New England Journal of Medicine|November 20, 1997
Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidismS J Silverberg, H G Bone, T B Marriott, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 30, 2012
Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosisD M Black, J P Bilezikian, S L Greenspan, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 29, 2019
Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonatesP D Miller, N Pannacciulli, J Malouf-Sierra, et al.
The Journal of Clinical Endocrinology and Metabolism|February 4, 2011
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone massHenry G Bone, Michael A Bolognese, Chui Kin Yuen, et al.
Obstetrics and Gynecology|April 12, 2003
Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosisMarjorie M Luckey, Nigel Gilchrist, Henry G Bone, et al.
The Journal of Family Planning and Reproductive Health Care|September 25, 2013
Comment on journal review of 'Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture'Lee L Lanza, Lisa J McQuay, Kenneth J Rothman, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 31, 2009
Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone densityHenry G Bone, Michael R McClung, Christian Roux, et al.
Pageof 20

Showing results (141-150 of 192) with videos related to

Sort By:
Pageof 20
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|September 24, 2018
The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studiesD L Kendler, A Chines, M L Brandi, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 4, 2011
Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trialsE Barrett-Connor, A S Swern, C M Hustad, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|October 20, 2019
Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumabD L Kendler, H G Bone, F Massari, et al.
The New England Journal of Medicine|November 20, 1997
Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidismS J Silverberg, H G Bone, T B Marriott, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 30, 2012
Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosisD M Black, J P Bilezikian, S L Greenspan, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 29, 2019
Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonatesP D Miller, N Pannacciulli, J Malouf-Sierra, et al.
The Journal of Clinical Endocrinology and Metabolism|February 4, 2011
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone massHenry G Bone, Michael A Bolognese, Chui Kin Yuen, et al.
Obstetrics and Gynecology|April 12, 2003
Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosisMarjorie M Luckey, Nigel Gilchrist, Henry G Bone, et al.
The Journal of Family Planning and Reproductive Health Care|September 25, 2013
Comment on journal review of 'Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture'Lee L Lanza, Lisa J McQuay, Kenneth J Rothman, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 31, 2009
Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone densityHenry G Bone, Michael R McClung, Christian Roux, et al.
Pageof 20